Cargando…

Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report

INTRODUCTION: Antidepressant drugs are effective therapies for major depressive disorder; however, they are frequently associated with side effects. Although there is some evidence for a relationship between genetic variation and side effects, little is known regarding the role of dynamic molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Yrondi, Antoine, Fiori, Laura M, Frey, Benicio N, Lam, Raymond W, MacQueen, Glenda M, Milev, Roumen, Müller, Daniel J, Foster, Jane A, Kennedy, Sidney H, Turecki, Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093997/
https://www.ncbi.nlm.nih.gov/pubmed/31819986
http://dx.doi.org/10.1093/ijnp/pyz066
_version_ 1783510386397413376
author Yrondi, Antoine
Fiori, Laura M
Frey, Benicio N
Lam, Raymond W
MacQueen, Glenda M
Milev, Roumen
Müller, Daniel J
Foster, Jane A
Kennedy, Sidney H
Turecki, Gustavo
author_facet Yrondi, Antoine
Fiori, Laura M
Frey, Benicio N
Lam, Raymond W
MacQueen, Glenda M
Milev, Roumen
Müller, Daniel J
Foster, Jane A
Kennedy, Sidney H
Turecki, Gustavo
author_sort Yrondi, Antoine
collection PubMed
description INTRODUCTION: Antidepressant drugs are effective therapies for major depressive disorder; however, they are frequently associated with side effects. Although there is some evidence for a relationship between genetic variation and side effects, little is known regarding the role of dynamic molecular factors as moderators of side effects. The aim of this study was to assess microRNA (miRNA) changes associated with side effects during escitalopram treatment and their downstream effects on target gene expression. METHODS: A total 160 patients with major depressive disorder from the CAN-BIND-1 cohort were included. Side effects were assessed with the Toronto Side Effect Scale after 2 weeks of treatment with escitalopram. We assessed the relationship between side effects and changes in peripheral expression of miRNAs between baseline and week 2. For miRNA whose expression changed, we used target prediction algorithms to identify putative messenger RNA (mRNA) targets and assessed their expression. RESULTS: Nausea was experienced by 42.5% of patients. We identified 45 miRNAs whose expression changed on initiation of escitalopram treatment, of which 10 displayed a negative association with intensity of nausea (miR15b-5p, miR17-5p, miR20a-5p, miR20b-5p, miR103a-3p, miR103b, miR106a-5p, miR182-5p, miR185-5p, and miR660-5p). Additionally, we found negative associations between 4 microRNAs (miR20a-5p, miR106a-5p, miR185-5p, miR660-5p) and mRNA targets. The expression of the miR185-5p target, CAMK2δ was significantly decreased [log 2 mean = −0.048 (0.233)] between weeks 0 and 2 (P = .01)]. CONCLUSIONS: We identified an overexpression of miR185-5p during escitalopram treatment of major depressive disorder, which was negatively associated with intensity of nausea, and identified a potential mRNA target that may mediate this effect.
format Online
Article
Text
id pubmed-7093997
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-70939972020-03-31 Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report Yrondi, Antoine Fiori, Laura M Frey, Benicio N Lam, Raymond W MacQueen, Glenda M Milev, Roumen Müller, Daniel J Foster, Jane A Kennedy, Sidney H Turecki, Gustavo Int J Neuropsychopharmacol Regular Research Articles INTRODUCTION: Antidepressant drugs are effective therapies for major depressive disorder; however, they are frequently associated with side effects. Although there is some evidence for a relationship between genetic variation and side effects, little is known regarding the role of dynamic molecular factors as moderators of side effects. The aim of this study was to assess microRNA (miRNA) changes associated with side effects during escitalopram treatment and their downstream effects on target gene expression. METHODS: A total 160 patients with major depressive disorder from the CAN-BIND-1 cohort were included. Side effects were assessed with the Toronto Side Effect Scale after 2 weeks of treatment with escitalopram. We assessed the relationship between side effects and changes in peripheral expression of miRNAs between baseline and week 2. For miRNA whose expression changed, we used target prediction algorithms to identify putative messenger RNA (mRNA) targets and assessed their expression. RESULTS: Nausea was experienced by 42.5% of patients. We identified 45 miRNAs whose expression changed on initiation of escitalopram treatment, of which 10 displayed a negative association with intensity of nausea (miR15b-5p, miR17-5p, miR20a-5p, miR20b-5p, miR103a-3p, miR103b, miR106a-5p, miR182-5p, miR185-5p, and miR660-5p). Additionally, we found negative associations between 4 microRNAs (miR20a-5p, miR106a-5p, miR185-5p, miR660-5p) and mRNA targets. The expression of the miR185-5p target, CAMK2δ was significantly decreased [log 2 mean = −0.048 (0.233)] between weeks 0 and 2 (P = .01)]. CONCLUSIONS: We identified an overexpression of miR185-5p during escitalopram treatment of major depressive disorder, which was negatively associated with intensity of nausea, and identified a potential mRNA target that may mediate this effect. Oxford University Press 2019-12-10 /pmc/articles/PMC7093997/ /pubmed/31819986 http://dx.doi.org/10.1093/ijnp/pyz066 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Regular Research Articles
Yrondi, Antoine
Fiori, Laura M
Frey, Benicio N
Lam, Raymond W
MacQueen, Glenda M
Milev, Roumen
Müller, Daniel J
Foster, Jane A
Kennedy, Sidney H
Turecki, Gustavo
Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
title Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
title_full Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
title_fullStr Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
title_full_unstemmed Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
title_short Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
title_sort association between side effects and blood microrna expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, escitalopram: a can-bind-1 report
topic Regular Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093997/
https://www.ncbi.nlm.nih.gov/pubmed/31819986
http://dx.doi.org/10.1093/ijnp/pyz066
work_keys_str_mv AT yrondiantoine associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report
AT fiorilauram associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report
AT freybenicion associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report
AT lamraymondw associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report
AT macqueenglendam associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report
AT milevroumen associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report
AT mullerdanielj associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report
AT fosterjanea associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report
AT kennedysidneyh associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report
AT tureckigustavo associationbetweensideeffectsandbloodmicrornaexpressionlevelsandtheirtargetedpathwaysinpatientswithmajordepressivedisordertreatedbyaselectiveserotoninreuptakeinhibitorescitalopramacanbind1report